Viewing Study NCT05272605


Ignite Creation Date: 2025-12-25 @ 3:24 AM
Ignite Modification Date: 2026-05-31 @ 8:56 PM
Study NCT ID: NCT05272605
Status: COMPLETED
Last Update Posted: 2023-05-15
First Post: 2022-03-03
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults
Sponsor: University of Melbourne
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None SARS-CoV-2 View
Keywords:

Keywords

Keyword Brief Keyword Text View
None COVID-19 View